Abstract: A compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Ca, Cb, Cd, and n are the same as described in the specification. Disclosed is a method of diagnosing or monitoring a patient suffering from cancer, the method comprising: administering a pharmaceutical composition comprising an effective amount of an active agent, wherein the active agent is the compound of Formula I, a pharmaceutically acceptable salt of any of the foregoing thereof, or a combination thereof, together with a pharmaceutically acceptable carrier to the patient and diagnosing or monitoring the patient by hyperpolarized 13C-MRI. Also disclosed is a method of synthesizing 1-13C-5-12C-diacid.

Abstract: A method of diagnosing or monitoring a patient suffering from cancer, the method comprising: administering a pharmaceutical composition comprising an effective amount of an active agent, wherein the active agent is [1-13C] N-acetyl cysteine, a deuterated derivative thereof, a pharmaceutically acceptable salt of any of the foregoing thereof, or a combination thereof, together with a pharmaceutically acceptable carrier to the patient; and diagnosing or monitoring the patient by hyperpolarized 13C-MRI. Also disclosed is a method of synthesizing [1-13C] N-acetyl cysteine or a deuterated derivative thereof.

Abstract: Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.

Abstract: An echo-based single point imaging (ESPI) system (10) providing high-resolution oxygen images of a sample is disclosed. The ESPI system (10) employs spin echo detection of the resonance from a spin probe and concurrent Single Point Imaging (SPI) for spatial encoding of the oxygen concentration within the sample. Images are derived by comparing spin echo intensities of two images reconstructed at two time points selected at identical time intervals on either side of a refocusing pulse, eliminating artifacts associated with sample magnetic susceptibility and field inhomogeneity effects.

Abstract: Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.

Abstract: An electron paramagnetic resonance imaging system that includes means for continuously irradiating a sample with RF irradiation; means for imposing on the sample a sinusoidally varying magnetic field along with rotating gradients for spatial encoding; means for directly detecting signal data from the sample, without using field modulation, while irradiating the sample with RF radiation continuously, the means for directly detecting having means for sweeping the sinusoidally varying magnetic field; and means for processing the signal data, using means including a digital signal processor.

Abstract: An echo-based single point imaging (ESPI) system (10) providing high-resolution oxygen images of a sample is disclosed. The ESPI system (10) employs spin echo detection of the resonance from a spin probe and concurrent Single Point Imaging (SPI) for spatial encoding of the oxygen concentration within the sample. Images are derived by comparing spin echo intensities of two images reconstructed at two time points selected at identical time intervals on either side of a refocusing pulse, eliminating artifacts associated with sample magnetic susceptibility and field inhomogeneity effects.

Abstract: A method of treating or preventing neurodegeneration in a mammal comprising administering to the mammal an effective amount of a stable nitroxide radical, such as Tempo1, as well as related methods.

Abstract: Disclosed is a method of treating a disease involving myelin and/or axonal loss, such as a demyelinating disease, in a mammal comprising administering a compound of formula I in which R1-R11 and n are defined herein. Also disclosed are methods of using a compound of formula I to treat neurodegeneration associated with inflammation and to reduce myelin and/or axonal loss.

Abstract: An electron paramagnetic resonance imaging system that includes means for continuously irradiating a sample with RF irradiation; means for imposing on the sample a sinusoidally varying magnetic field along with rotating gradients for spatial encoding; means for directly detecting signal data from the sample, without using field modulation, while irradiating the sample with RF radiation continuously, the means for directly detecting having means for sweeping the sinusoidally varying magnetic field; and means for processing the signal data, using means including a digital signal processor.

Abstract: The present invention provides a method for the prophylactic and therapeutic treatment of cancer. The method comprises administering to an animal, preferably a mammal, more preferably a human, at risk for developing a cancer or having a cancer a nitroxide or a prodrug thereof, wherein the nitroxide or prodrug thereof preferably is alicyclic or heterocyclic and more preferably is a compound of Formula (I) or Formula (II): in an amount sufficient to prevent or treat said cancer, wherein said cancer is susceptible to prevention or treatment by said nitroxide or prodrug thereof.